STOCK TITAN

Keller Rohrback Files Suit Against Athira Pharma for Misrepresentations in IPO Registration Statement

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Negative)
Tags

Keller Rohrback and co-counsel Longman Law, P.C. filed a class action lawsuit against Athira Pharma, Inc. (“Athira”) (NASDAQ: ATHA), certain of its officers and directors, and the underwriters of the IPO of Athira common stock. The suit, entitled Timothy Slyne, et al. v. Athira Pharma, Inc., et al., was filed in the Western District of Washington on behalf of purchasers of ATHA common stock who either purchased shares in the September 2020 initial public offering (IPO) or on the open market that can be traced to the IPO. The lawsuit seeks remedies pursuant to the Securities Act of 1933.

The lawsuit alleges that Defendants misrepresented and omitted crucial truths regarding Athira Chief Executive Officer and President Dr. Leen Kawas in the Registration Statement for the IPO. Athira announced after close of trading on June 17, 2021 that the Athira Board placed Dr. Kawas on temporary leave in light of claims that she falsified research results in various academic papers. This news caused Athira’s stock to plunge approximately 40% from $18.24 to $11.15 per share—well below the $17.00 IPO price.

Athira’s misrepresentations about its President and CEO and omission regarding the alleged research misconduct caused injury to all those who purchased Athira common stock pursuant or traceable to the IPO. If you purchased or acquired ATHA common stock pursuant to or traceable to the IPO, please contact Keller Rohrback’s securities team at investor@kellerrohrback.com or (800) 776-6044.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS A LEAD PLAINTIFF.

About Keller Rohrback L.L.P.

With offices in Seattle, Phoenix, New York, Oakland, Santa Barbara, and Missoula, Keller Rohrback serves as lead and co-lead counsel in class actions throughout the country. The firm has a track record for holding corporations accountable for wrongdoing and has achieved large settlements on behalf of its clients, including a $142 million settlement in the Wells Fargo Unauthorized Accounts Scandal.

Attorney advertising. Prior results do not guarantee a similar outcome. This press release may be considered Attorney Advertising in some jurisdictions under applicable laws and ethical rules. Please see krcomplexlit.com for more details.

Athira Pharma, Inc.

NASDAQ:ATHA

ATHA Rankings

ATHA Latest News

ATHA Stock Data

96.58M
26.94M
2.19%
62.85%
2.63%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
BOTHELL

About ATHA

m3 biotechnology is an innovative therapeutics company that has a novel platform of disease-modifying regenerative small molecules, particularly relevant to neurodegenerative diseases. the lead compound modifies growth-factor systems, where the activation is expected to stop disease progression and even restore lost function. the company’s research has been funded by the alzheimer’s drug discovery foundation, washington’s life sciences discovery fund, w fund, wrf capital, dolby family ventures and other private investors. where current and emerging therapies are focused primarily on disease symptoms and improving the quality of life of patients suffering from disease, m3 differentiates itself from the competition by addressing the neurodegenerative process, providing a cost-effective solution and feasible delivery mechanism. our strategy is to leverage our patented and proprietary technologies to develop small molecule modulators with a primary focus on altering the course of alzheimer